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ABSTRACT
OBJECTIVE
To assess the effects of different oral antithrombotic
drugs that prevent saphenous vein graft failure in
patients undergoing coronary artery bypass graft
surgery.
DESIGN
Systematic review and network meta-analysis.
DATA SOURCES
Medline, Embase, Web of Science, CINAHL, and the
Cochrane Library from inception to 25 January 2019.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Randomised controlled trials of participants (aged
≥18) who received oral antithrombotic drugs
(antiplatelets or anticoagulants) to prevent saphenous
vein graft failure after coronary artery bypass graft
surgery.
MAIN OUTCOME MEASURES
The primary efficacy endpoint was saphenous vein
graft failure and the primary safety endpoint was
major bleeding. Secondary endpoints were myocardial
infarction and death.
RESULTS
This review identified 3266 citations, and 21 articles
that related to 20 randomised controlled trials were
included in the network meta-analysis. These 20
trials comprised 4803 participants and investigated
nine different interventions (eight active and one
placebo). Moderate certainty evidence supports the
use of dual antiplatelet therapy with either aspirin
plus ticagrelor (odds ratio 0.50, 95% confidence

WHAT IS ALREADY KNOWN ON THIS TOPIC
Aspirin is considered the preferred antiplatelet drug to prevent saphenous vein
graft failure after coronary artery bypass surgery
Uncertainty remains about the benefits of adding a P2Y12 inhibitor or direct oral
anticoagulant to aspirin monotherapy after bypass surgery

WHAT THIS STUDY ADDS
Dual antiplatelet therapy with either aspirin plus ticagrelor or aspirin plus
clopidogrel was more efficacious than aspirin monotherapy in preventing
saphenous vein graft failure after coronary artery bypass surgery
No strong evidence was found of differences in major bleeding, myocardial
infarction, and death for different antithrombotics compared with aspirin
monotherapy
Future guideline updates are needed to optimise antithrombotic management of
patients undergoing coronary artery bypass graft surgery
Dual antiplatelet therapy with aspirin plus ticagrelor or aspirin plus clopidogrel
could be considered for most patients after surgery
the bmj | BMJ 2019;367:l5476 | doi: 10.1136/bmj.l5476

interval 0.31 to 0.79, number needed to treat 10) or
aspirin plus clopidogrel (0.60, 0.42 to 0.86, 19) to
reduce saphenous vein graft failure when compared
with aspirin monotherapy. The study found no strong
evidence of differences in major bleeding, myocardial
infarction, and death among different antithrombotic
therapies. The possibility of intransitivity could not
be ruled out; however, between-trial heterogeneity
and incoherence were low in all included analyses.
Sensitivity analysis using per graft data did not
change the effect estimates.
CONCLUSIONS
The results of this network meta-analysis suggest an
important absolute benefit of adding ticagrelor or
clopidogrel to aspirin to prevent saphenous vein graft
failure after coronary artery bypass graft surgery. Dual
antiplatelet therapy after surgery should be tailored to
the patient by balancing the safety and efficacy profile
of the drug intervention against important patient
outcomes.
STUDY REGISTRATION
PROSPERO registration number CRD42017065678.

Introduction
Coronary artery bypass graft surgery is the preferred
treatment for many patients with multivessel coronary
artery disease.1 2 However, patients undergoing this
procedure remain at risk of subsequent major adverse
cardiovascular events, mainly caused by associated
progression of native coronary artery disease, vascular
damage, or saphenous vein graft failure.3-7 Previous
studies have shown rates of saphenous vein graft
failure of up to 30-40% in the first year8 9 and up to
70% beyond 10 years after coronary artery bypass
graft surgery.8 10-13 Despite its relatively high early
failure rates, saphenous vein graft remains the most
commonly used graft in contemporary coronary artery
bypass graft trials.14-17
Aspirin is considered the preferred antiplatelet
drug to prevent saphenous vein graft failure after
coronary artery bypass graft (class I, level of
evidence A).18 Updated meta-analyses support this
recommendation, but at a cost of increasing the
risk of bleeding.19-21 Uncertainty remains about
the benefits of adding a P2Y12 inhibitor or oral
anticoagulant to aspirin monotherapy. There is
emerging evidence on the potential benefits of dual
antiplatelet therapy with aspirin and clopidogrel or
ticagrelor after coronary artery bypass graft surgery,
but these combinations have not been directly
1
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compared with other antithrombotic therapies in
randomised controlled trials. Additionally, no studies
have been published to compare the effects of all
available oral antithrombotic drugs (antiplatelets and
anticoagulants) for the prevention of saphenous vein
graft failure after coronary artery bypass graft surgery
within a single analytical framework. Therefore,
in this study we aimed to systematically review
randomised controlled trials that assessed the effects
of oral antithrombotic drugs to prevent saphenous
vein graft failure in patients undergoing coronary
artery bypass graft surgery. We also evaluated the
comparative efficacy and harms of these drugs by
using a network meta-analysis.

Methods
Literature search
This systematic review and network meta-analysis
is reported following the Preferred Reporting Items
for Systematic reviews and Meta-analyses (PRISMA)
extension statement for network meta-analysis22
(fig 1). This study is registered with PROSPERO
(CRD42017065678) and the protocol has been peer
reviewed and published in BMJ Open.23
We conducted a search of Medline, Embase, Web
of Science, CINAHL, and the Cochrane Library from
their inception to 25 January 2019. We also performed
a grey literature search and checked reference lists of
relevant reviews and eligible randomised controlled

trials to ensure a comprehensive search.23 The full
search strategy has been published in the protocol.23

Data selection
Studies were eligible for inclusion if they consisted of
patients (≥18 years) who underwent coronary artery
bypass graft surgery with at least one saphenous vein
graft; if they compared oral antithrombotic regimens
with each other or placebo; and if they evaluated
saphenous vein graft failure, regardless of unit of
analysis and drug regimens. Antithrombotic drugs
included in this review were aspirin, clopidogrel,
ticagrelor, vitamin K antagonists (warfarin, aceno
coumarol, phenprocoumon), and rivaroxaban; dual
antiplatelet therapy included aspirin plus clopidogrel
or aspirin plus ticagrelor; and dual therapy included
aspirin plus rivaroxaban. We did not include aspirin
plus dipyridamole because this combination is no
longer used in clinical practice for patients with
coronary artery disease. We considered aspirin
monotherapy as a single intervention regardless of
whether aspirin was interrupted or continuously
administered before coronary artery bypass graft
surgery because a recent meta-analysis showed no
difference between these two approaches.21
Data identification and extraction
Two investigators (KS and AAH) independently
screened articles by title, abstract, and full text

3266
Records identiﬁed through database searching

1307
Records screened aer duplicates removed
1179
Records excluded
128
Full text articles assessed for eligibility
105
Full text articles excluded
46 Duplicate
13 Wrong outcome
4 Wrong study design
26 Wrong intervention
4 Wrong patient population
4 Non-extractable data
1 Non-English
7 Ongoing trials
23
Studies included in qualitative synthesis

20
Studies included in quantitative synthesis (meta-analysis), unique randomised controlled trials
Reported in 21 manuscripts
Fig 1 | PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram
2
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Table 1 | Characteristics of the included randomised controlled trials

Study, year
(sample size)
Pantely, 1979
(n=47)

SVG patency
assessment method
(unit of analysis), time
Time of
from randomisation to
drug
initiation
Treatment SVG patency
after CABG duration assessment
Angiography
+3 days
6 months (per patient and per
graft), 6 months

Relevant study arms
VKA: warfarin
(INR target: NR);
C: no study medication

No of any graft/
SVG per patient*

Age (years)

Male (%)

Effect size
for SVGF, OR
(95% CI)

VKA: 2.85/2.85;
C: 2.54/2.54

VKA: 56±8;
C: 52±8

VKA: 69.2;
C: 83.3

VKA v C: 1.04
(0.26 to 4.18)

—

VKA: 92.9;
ASA: 82.0;
C: 87.3

McEnany, 1982
(n=216)

+3 to
4 days

Angiography
(per patient and per
12 months
graft), 21.5 months
(range 1-47 months)

VKA: warfarin
(INR target: 1.5-2);
ASA: 600 mg BID;
C: matching placebo

VKA: 1.91/1.91;
ASA: 2.03/2.03;
C: 2.00/2.00

Sharma, 1983
(n=116)
Lorenz, 1984
(n=60)
Brown, 1985
(n=98)

+3 to
5 days

12 months

Angiography (per patient
and per graft), 12 months
Angiography (per patient
4 months
and per graft), 4 months
Angiography (per patient
12 months
and per graft), 12 months
Angiography (per graft),
12 months 12 months
(range 62-527 days)
Angiography (per patient
12 months and per graft), 12 months
(range 222-430 days)

ASA: 325 mg TID;
C: no study medication
ASA: 100 mg OD;
C: matching placebo
ASA: 325 mg TID;
C: matching placebo

ASA: 2.20/2.20;
C: 2.20/2.20
ASA:1.90/1.90;
C: 2.23/2.23
ASA: 3.10/3.10;
C: 3.30/3.30

ASA: 325 mg OD;
C: matching placebo
ASA: 324 mg OD;
C: matching placebo

Goldman, 1989
(n=98)

+24 hours
+67±
27 hours
−12 hours

Gavaghan, 1991
+1 hours
(n=237)
Van der Meer,
1993 (n=635)

−12 hours;
24 hours

Angiography
12 months (per patient and
per graft), 12 months

Hockings, 1993
(n=140)

−7 days

6 months

Angiography
(per patient), 6 months

Mujanovic, 2009 Immediately
3 months
(n=20)
postop

Angiography (per graft),
3 months

Gao, 2009
(n=197)

+1 day

Unclear

64-MSCTA (per graft),
12 months

Kulik, 2010
(n=113)

0 day

Angiography
12 months (per patient and
per graft), 12 months

Gao, 2010
(n=249)

≤ +48
hours

3 months

MSCTA (per graft),
3 months

Sun, 2010
(n=99)

+6 to
48 hours

1 month

MSCTA (per patient),
50 days

Mannacio, 2012
(n=300)

+28±
12 hours

12 months

64-MSCTA (per graft),
12 months

Saw, 2016
(n=70)

+58 to
59 hours

3 months

128/320-MSCTA
(per graft), 12 months

Slim, 2016
(n=20)

+6 hours

8 months

128-MSCTA (per graft),
12 months

Zhao, 2018
(n=500)

+0 to
24 hours

MSCTA (per graft),
12 months
12 months

Xu, 2018
(n=140)

NR

1 month

MSCTA (per graft),
1 month

VKA: 4 mg acenocoumarol
or 6 mg phenprocoumon
(INR target: 2.8-4.8); ASA:
50 mg OD
ASA: 100 mg OD;
C: matching placebo
ASA+clopi: 100 and 75 mg
OD, respectively; ASA:
100 mg OD
ASA+clopi: 100 and 75 mg
OD, respectively; clopi:
75 mg OD
ASA+clopi: 162 and
75 mg OD, respectively;
ASA: 162 mg OD and
matching placebo
ASA+clopi: 100 and 75 mg
OD, respectively; ASA:
100 mg OD
ASA+clopi: 81 and 75 mg
OD, respectively; ASA:
81 mg OD
ASA+clopi: 100 and 75 mg
OD, respectively; ASA:
100 mg OD
ASA+tica: 81 mg OD and
90 mg BID, respectively;
ASA: 81 mg OD and
matching placebo
ASA+clopi: 81 and 75 mg
OD, respectively; ASA:
81 mg OD and matching
placebo
ASA+tica: 100 mg OD and
90 mg BID, respectively;
tica: 90 BID; ASA: 100 OD

VKA v C: 0.55
(0.20 to 1.46); VKA v
ASA: 0.69 (0.26 to 1.84);
ASA v C: 0.79 (0.32 to
1.96)
ASA v C: 0.94
(0.42 to 2.13)
ASA v C: 0.23
(0.06 to 0.79)
ASA v C: 0.52
(0.20 to 1.32)

ASA: 55±10;
C: 55±6

ASA: 100;
C: 100
ASA: 82.8;
C: 90.3

—

—

Overall: -/3.20

ASA: 59±8;
C: 58±8

ASA: 100;
C: 100

ASA v C: 0.68
(0.39 to 1.18)

ASA: -/3.40;
C: -/3.60

ASA:56±8;
C: 56±7

ASA: 86.6;
C: 83.6

ASA v C: 0.31
(0.15 to 0.63)

VKA: -/3.10;
ASA: -/2.80

VKA: 58±8;
ASA: 58±8

VKA: 88.0;
ASA: 87.0

VKA v ASA: 0.99
(0.67 to 1.46)

ASA: 60±9;
C: 60±9
ASA+clopi:
ASA+clopi: 2.9/2.9;
58±8.5; ASA:
ASA: 2.7/2.7
60±8.5
ASA+clopi:
ASA+clopi:
2.66/1.71; clopi:
61±10; clopi:
2.49/1.51
62±9.9

ASA: 94.0;
C: 92.3

ASA v C: 0.53
(0.16 to 1.71)

—

ASA+clopi v ASA:
0.16 (0.03 to 0.98)

ASA+clopi:
82.1;
clopi: 83.3

ASA+clopi v clopi:
0.52 (0.17 to 1.60)

ASA+clopi:
3.6/2.30; ASA:
3.4/2.24

ASA+clopi:
65±7.5; ASA:
68±7.4

ASA+clopi:
91.1;
ASA: 87.7

ASA+clopi v ASA
1.34† (0.39 to 4.62)

ASA+clopi:
3.18/2.14; ASA:
3.11/2.10
ASA+clopi:
4.03/2.35; ASA:
3.95/2.30
ASA+clopi:
3.1/1.78; ASA:
3.2/1.87

ASA+clopi:
58±8.3; ASA:
60±7.9
ASA+clopi:
66±9.4; ASA:
65±9.3
ASA+clopi:
59±7.7; ASA:
59±8.3

ASA+clopi:
82.3;
ASA: 83.8
ASA+clopi:
93.9;
ASA: 86.0
ASA+clopi:
73.3;
ASA: 75.3

ASA+tica:
2.49/1.14; ASA:
3.43/1.69

ASA+tica:
62±7.5; ASA:
63±9.7

ASA+tica: 85.7;
ASA:88.6

ASA+tica v ASA: 0.45
(0.13 to 1.56)

ASA+clopi:
3.00/2.00; ASA:
3.38/2.38

—

—

ASA+clopi v ASA:
0.76 (0.20 to 2.95)

ASA+tica:
3.76/2.90; tica:
3.83/2.94;
ASA: 3.76/2.92

ASA+tica:
64±8.2; tica:
63±8.3; ASA:
64±8.1

ASA+tica: 79.8;
tica: 80.7;
ASA: 84.9

ASA+tica v tica: 0.70
(0.44 to 1.09); ASA+tica
v ASA: 0.47 (0.27 to
0.80); tica v ASA: 0.68
(0.46 to 1.01)

ASA+tica:
59±8.9;
ASA+clopi:
60±7.5

ASA+tica: 77.1; ASA+tica v ASA+clopi:
ASA+clopi: 72.9 0.81 (0.24 to 2.73)

—

ASA: 3.14/2.56;
C: 3.52/2.79

ASA+tica: 100 mg OD and
90 mg BID, respectively;
ASA+tica: -/2.51;
ASA+clopi: 100 mg OD and ASA+clopi: -/2.59
75 mg OD, respectively

ASA+clopi v ASA:
0.55 (0.29 to 1.04)
ASA+clopi v ASA:
1.20 (0.33 to 4.32)
ASA+clopi v ASA:
0.55 (0.29 to 1.02)

ASA+riva: v riva: 1.24
(0.87 to 1.78); ASA+riva
NR
v ASA: 1.13 (0.80 to
1.62); riva v ASA: 0.91
(0.63 to 1.33)
Values are presented as mean±standard deviation or No (%) unless stated otherwise. ASA=aspirin; BID=twice a day; C=control; CABG=coronary artery bypass graft; clopi=clopidogrel;
INR=international normalised ratio; MSCT=multislice computed tomography angiography; NR=not reported; OAC=oral anticoagulation; OD=once a day; OR=odds ratio; riva= rivaroxaban; SVG=saphenous vein graft; SVGF=saphenous vein graft failure; tica=ticagrelor; TID=three times a day; VKA=vitamin K antagonist.
*Data that were not reported in the original studies were calculated from total number of grafts/number of patients enrolled.
†Calculated from Hage24 reporting long term data.
Lamy, 2018
(n=1448)

+4 to
14 days

MSCTA (per graft),
12 months

the bmj | BMJ 2019;367:l5476 | doi: 10.1136/bmj.l5476

ASA+riva: 100 mg OD and
2.5 mg BID, respectively;
riva: 5 mg BID;
ASA: 100 mg OD

ASA+riva: -/2.00;
riva: -/2.00;
ASA: -/2.00

ASA+riva:
66±7.8; riva:
65±7.9; ASA:
66±8.5

ASA+riva: 78.3;
riva: 81.2;
ASA: 82.3

3
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according to prespecified inclusion criteria. The
full text reports of potentially relevant studies were
retrieved, and data on study and patient characteristics,
treatment strategies, and results of all included studies
were then independently extracted (KS and AAH/
TC) using a data extraction form. Any discrepancies
were resolved by consensus after consulting a third
investigator (RB).

Outcome measures
The primary efficacy outcome was the incidence of
saphenous vein graft failure, defined as participants
with at least one occluded saphenous vein graft as
assessed by either invasive angiogram or computed
tomography (table 1 and supplementary table 1).
We prespecified a sequence in the protocol23 in case
the overall preferred definition of total occlusion
was not used. Because not all the included studies
expressed saphenous vein graft failure on a per
patient basis, we also included studies that reported
per graft data in our base case analysis to increase
the totality of evidence. We made the decision about
combining per patient and per graft data after we
compared the results from per patient14-16 25-37 and per
graft14-17 24-36 38-40 (accounting for clustering effects)
meta-analyses. The results for magnitude and direc
tion of effect estimates were consistent and there
were large overlapping 95% confidence intervals of
effect sizes in most comparisons. Because a sensitivity
analysis showed the per graft network meta-analysis
and the base case network meta-analysis did not differ
substantially, the inference for our base case analysis
was made on per patient basis. This approach is
clinically preferable given that treatments are applied
to patients (and not grafts).
We calculated and used effective sample size instead
of originally reported outcome data to account for
clustering effects for per graft data.41-43 The effective
sample size was estimated by using a design effect
that includes an intra cluster correlation coefficient.43
We obtained the intra cluster correlation coefficient
needed to calculate the effective sample size from
an external source.42 The size of the intra cluster
correlation coefficient and the number of observations
sampled within each cluster influence the power
of the study.43 We used an intra cluster correlation
coefficient of 0.177 for this review.42 Additionally, if
studies reported the incidence of saphenous vein graft
failure at multiple time points, we included the longest
available follow-up period in our base case analysis.
The primary safety outcome was the incidence of
major bleeding. Secondary outcomes were all cause
mortality and myocardial infarction. These outcomes
were binary and defined according to the definitions
of the study authors (table 1 and supplementary table
1). We collected data on major adverse cardiac and
cerebrovascular events, heart failure, minor bleeding,
red blood cell transfusion, and admission to hospital
owing to a cardiovascular cause; however, because
these data were sparse, we did not report them in our
study.
4

Risk of bias and certainty assessment
We assessed the risk of bias in included studies by
using the Cochrane Collaboration tool for randomised
trials 2.044 for each outcome. We graded the certainty
of direct and network evidence by using the Grade of
Recommendations Assessment, Development, and
Evaluation (GRADE) for network meta-analysis.45
Statistical analyses
We performed a frequentist network meta-analysis
of aggregate data to obtain network estimates for
the aforementioned outcomes of interest. The model
framework used random effects to allow for apparent
heterogeneity among studies in treatment comparison
effects. We conducted a pairwise meta-analysis to
generate direct estimates for outcomes by using a
random effects model. Transitivity assumption, the
distribution of patient and study characteristics that
modify treatment effects (effect modifiers) across
treatment comparisons, was explored to assess
whether these characteristics were sufficiently similar
between comparisons. Additionally, we evaluated
incoherence assumption (the statistical disagreement
between direct and indirect evidence in a closed loop)
locally using a loop specific approach, and globally
using a design by treatment interaction model.46 We
used surface under the cumulative ranking (SUCRA)47
to rank the intervention’s hierarchy in the network
meta-analysis and then we estimated mean ranks. We
used the comparison adjusted funnel plot to explore
the potential for publication bias.47
We performed sensitivity analyses to assess the
robustness of the model for the primary outcomes.
We visually compared the results of the base case
analysis with those of the per graft and in-trial data
(to exclude the legacy effect of drug interventions)
analyses, and excluding trials with off pump coronary
artery bypass graft only. We performed an “all missing
failure” analysis to explore the impact of missing data;
this analysis assumed that all missing patients had a
negative event.48 All outcomes of interest were binary
and the relative treatment effects were reported as odds
ratios with 95% confidence intervals. All analyses were
done in Stata version 14 using the network command.
Patient and public involvement
There was no patient or public involvement around
the research question or conception and design of the
study. Because of the nature of the study, there was no
patient or public involvement in any recruitment or
conduction of the study. There was no patient or public
involvement in measuring the outcomes, in providing
interpretations of the findings, or writing of the results.
Results
Data selection
Our systematic search identified 3266 citations
published between 1979 and 2019. Of these, we
included 21 articles14-17 24-40 that related to 20
unique parallel group randomised controlled trials
in the network meta-analysis. These trials comprised
doi: 10.1136/bmj.l5476 | BMJ 2019;367:l5476 | the bmj
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4803 participants and investigated nine different
interventions (eight active and one placebo) (fig 1);
three trials had three eligible arms and the remaining
trials had two eligible arms.16 17 26
The study sample size ranged from 20 to 1448
patients, patient age ranged from 44 to 83 years,
83% were male, and 83% underwent elective (stable
coronary artery disease) surgery. The number of
saphenous vein grafts ranged from 1.14 to 3.60 per
patient, and drug interventions were started from
seven days before coronary artery bypass graft surgery
to 14 days after the procedure. The duration of followup ranged from one month to eight years. Assessment
of saphenous vein graft failure was performed by
either invasive angiography or computed tomography
(table 114-17 24-40 and supplementary table 1).
Across comparisons, the distribution of baseline
characteristics by treatment was generally balanced,
except for the type of coronary artery bypass graft
technique (on pump versus off pump coronary artery
bypass graft), and the timing of drug initiation (table
2). Information on antifibrinolytic use was not reported
because of limited data.

Mixed treatment meta-analyses
Primary efficacy outcome
The network of treatment comparisons for saphenous
vein graft failure included nine individual nodes (fig
2, top panel). Each of the nodes represents placebo or
different drug interventions; aspirin was the most well
connected intervention with all other interventions
directly linked to it, except for clopidogrel monotherapy.
Figure 3 (top panel) shows network estimates of
treatment effect on saphenous vein graft failure

for different interventions compared with aspirin
monotherapy. Network meta-analysis showed that dual
antiplatelet therapy with either aspirin plus ticagrelor
(odds ratio 0.50, 95% confidence interval 0.31 to 0.79,
number needed to treat 10) or aspirin plus clopidogrel
(0.60, 0.42 to 0.86, 19) was more efficacious than
aspirin monotherapy to prevent saphenous vein graft
failure. Pooled effect sizes also suggested that all active
interventions reduced saphenous vein graft failure
compared with placebo. However, the evidence does
not support the efficacy of clopidogrel monotherapy in
reducing saphenous vein graft failure compared with
placebo (fig 3, top panel). According to SUCRA values,
the top two ranked interventions for the reduction of
saphenous vein graft failure were dual antiplatelet
therapy with aspirin plus ticagrelor (94.4) and aspirin
plus clopidogrel (85.3; table 3).
In our sensitivity analyses we used per graft data,
excluded off pump only trials,35 36 and accounted
for missing outcome data. The study effect estimates
(supplementary table 2) and SUCRA values
(supplementary table 3) did not substantially
change. One of the included studies in our network
meta-analysis reported post-trial24 (used in the base
case analysis) and in-trial37 data. We performed a
sensitivity analysis to explore the legacy effect of drug
interventions by using in-trial data. Effect estimates
and SUCRA values did not substantially change
compared with the base case analysis (supplementary
tables 2 and 3, respectively).

Primary safety outcome

Eleven randomised controlled trials15-17 24 26 31 33 34 35 39 40
comprising 3745 patients reported the incidence

Table 2 | Summary of baseline and procedural characteristics of patients across different treatment comparisons
Treatment comparison (No of RCTs)
ASA v
Characteristics placebo
(n=7)
(No of RCTs*)
Age (n=17)
58±7.7
Male
1212/1278
(n=16)
(95)
Diabetes
45/560
(n=14)
(8)
Hypertension
528/1218
(n=15)
(43)
Dyslipidaemia
27/116
(n=9)
(23)
Prior MI
703/1076
(n=13)
(65)
Prior PCI
NR
(n=5)
Prior CVA
NR
(n=3)
OPCABG
862/862
(n=16)
(100)
Elective surgery 932/1006
(n=16)
(93)
Time of drug
14 preop
initiation
to 5 postop
(range) (n=20) days

ASA+riva
v aspirin
(n=1)
66±8.1
774/965
(80)
413/965
(43)

ASA+riva
v riva
(n=1)
66±7.8
785/985
(80)
393/985
(40)

NR

NR

NR

NR

74/111
(67)

VKA v ASA
(n=2)
58±8
632/722
(88)
74/722
(10)
250/722
(35)
271/616
(44)
401/722
(56)

Riva v
Tica v ASA ASA
(n=1)
(n=1)
64±8.2
65±8.2
275/332 773/946
(83)
(82)
142/332 412/946
(43)
(44)
242/332
NR
(73)
243/332
NR
(73)
103/332 351/946
(31)
(37)

350/965
(36)

355/985
(36)

NR

NR

NR

NR

NR

NR

29/946
(3.1)
235/946
(25)
582/946
(61)
4-14
postop
days

36/965
(4.0)
228/965
(24)
599/965
(62)
4-14
postop
days

37/985
(3.8)
245/985
(25)
601/985
(61)
4-14
postop
days

VKA v
control
(n=2)
53±8
129/148
(87)
18/111
(16)
20/111
(18)

NR

NR
37/37
(100)
73/145
(50)
3-4
postop
days

35/332
(11)
616/616
82/332
(100)
(25)
695/755
332/332
(92)
(100)
12 preop
Within 24
hours to 4
postop
postop days hours
NR

ASA+clopi
v ASA
(n=6)
61±8.16
599/736
(81)
168/756
(22)
417/756
(55)
426/736
(58)
253/623
(41)
77/524
(15)
16/436
(3.7)
321/776
(41)
776/776
(100)
Immediately
postop to 48
hours

ASA+clopi
v clopi
(n=1)
62±9.94
163/197
(83)
108/197
(55)
125/197
(64)
41/197
(21)
105/197
(53)
24/197
(12)

NR
124/197
(63)
186/197
(94)
1 day

ASA+tica
v ASA
(n=2)
63±8.24
336/404
(83)
163/404
(40)
301/404
(75)
299/404
(74)
108/404
(27)
8/70
(11)
48/334
(14)
85/334
(25)
381/404
(94)
Within 2459 postop
hours

ASA+clopi
v ASA+tica
(n=1)
60±8.2
105/140
(75)
94/140
(67)
92/140
(66)

NR
53/140
(38)
18/140
(13)
NR
26/140
(19)
140/140
(100)
NR

ASA+tica v
tica (n=1)
64±8.3
183/217
(84)
124/217
(57)
176/217
(81)
245/292
(84)
102/217
(47)

NR
75/217
(35)
88/217
(41)
217/217
(100)
Within 24
postop
hours

Values presented as mean±standard deviation or No (%) unless stated otherwise. ASA=aspirin; clopi=clopidogrel; CVA=cerebrovascular accident; MI=myocardial infarction; NR=not reported;
OPCABG=off pump coronary artery bypass graft; PCI=percutaneous coronary intervention; RCT=randomised controlled trial; riva=rivaroxaban; tica=ticagrelor; VKA=vitamin K antagonist.
*Number of RCTs reporting data.
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of major bleeding. The network diagram of eligible
treatment comparisons included eight individual nodes
(fig 2, bottom panel). Each of the nodes represents
different active interventions or placebo, in which aspirin
monotherapy was the most well connected intervention
with all other interventions directly linked to it. Figure
3 (bottom panel) shows network estimates of treatment
effect on major bleeding for different interventions
compared with aspirin monotherapy. Network metaanalyses showed no evidence of differences among all
possible treatment comparisons. Pooled effect sizes
also suggested that all active interventions increased
bleeding compared with placebo, although without

substantial statistical evidence (fig 3, bottom panel).
According to SUCRA values, after placebo (84.4), the
top ranked intervention associated with fewer major
bleeding events was dual antiplatelet therapy with
aspirin plus clopidogrel (66.5; table 3).
Sensitivity analyses that excluded one off pump
only trial,35 accounted for missing outcome data, and
used in-trial data did not show substantial changes
in study effect estimates (supplementary table 4) and
SUCRA values (supplementary table 5). When we used
in-trial data for analysis, aspirin monotherapy and its
combination with rivaroxaban obtained a higher rank
(supplementary table 5).

Saphenous vein gra failure

Aspirin and ticagrelor

Vit K A
1 trial

2 trials

Clopidogrel

2 trials

1 trial

Aspirin and
clopidogrel

6 trials
Aspirin

1 trial

2 trials
7 trials

Placebo

1 trial

1 trial

1 trial
Rivaroxaban

1 trial

Aspirin and rivaroxaban

Ticagrelor

Major bleeding
Aspirin and ticagrelor
1 trial
Vit K A

Aspirin and
clopidogrel

2 trials
2 trials

4 trials

1 trial

2 trials

Aspirin

1 trial

Placebo
1 trial

Aspirin and
rivaroxaban

1 trial

1 trial
Rivaroxaban

1 trial
Ticagrelor

Fig 2 | Network of treatment comparisons for saphenous vein graft failure (primary efficacy outcome) and major
bleeding (primary safety outcome). Each node represents different active interventions or placebo. Size of nodes
is proportional to number of studies comparing respective nodes. Increasing thickness of lines between nodes
is proportional to number of randomly assigned patients contributing to direct comparisons. Vit K A=vitamin K
antagonist
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Secondary outcomes

Ten randomised controlled trials14 15 25 26 29 30 31 33 37 39
comprising 1921 patients reported all cause mortality,
and 12 randomised controlled trials14-17 24 26 31 33 34 35 39 40
comprising 3994 patients reported myocardial infarction.
Figure 4 shows networks of treatment comparisons for
secondary outcomes. Figure 5 summarises results
for secondary outcomes. Network meta-analyses
showed no evidence of differences among all possible
comparisons for secondary outcomes (all cause
mortality and myocardial infarction). Supplementary
table 6 presents SUCRA values. The included
randomised controlled trials sparsely reported
other pre
specified secondary outcomes; therefore,
network meta-analyses were not conducted for these
outcomes.

Risk of bias and certainty of evidence
We judged two randomised controlled trials27 39 to
have a high risk of bias arising from the randomisation
process and five randomised controlled trials24-26 30 40
to have a high risk of bias because of missing outcome
data (supplementary table 7). Five of the trials26 29 36 38 39
had some concerns about measurement of the outcome
and three randomised controlled trials27 36 38 had
some concerns about bias from selective reporting of
outcomes. We judged only five unique trials15 16 35 37 40
to have a low risk of bias due to deviation from
intended interventions. Overall, we judged eight trials
(40%)24-28 30 39 40 to have a high risk of bias, primarily
owing to failure to blind and missing outcome data.
Of trials reporting incomplete outcome data, 10
trials14-17 27 33-35 37 39 performed intention to treat

Saphenous vein gra failure
Placebo

0.64
0.56
0.56
0.45
0.48
0.28
0.60
0.34
(0.19 to 2.16) (0.42 to 0.76) (0.37 to 0.86) (0.26 to 0.79) (0.30 to 0.77) (0.16 to 0.48) (0.38 to 0.98) (0.21 to 0.54)
Clopidogrel

0.88
0.88
0.70
0.75
0.44
0.93
0.52
(0.27 to 2.84) (0.26 to 2.98) (0.20 to 2.47) (0.22 to 2.55) (0.13 to 1.52) (0.27 to 3.16) (0.17 to 1.60)
Aspirin

1.00
0.80
0.85
0.50
1.06
0.60
(0.71 to 1.41) (0.49 to 1.29) (0.59 to 1.23) (0.31 to 0.79) (0.75 to 1.50) (0.42 to 0.86)
0.80
0.85
0.50
1.06
0.60
Vitamin K
antagonists (0.44 to 1.44) (0.51 to 1.41) (0.28 to 0.88) (0.65 to 1.73) (0.36 to 0.98)
Ticagrelor

1.07
0.62
1.33
0.75
(0.58 to 1.95) (0.37 to 1.05) (0.73 to 2.40) (0.42 to 1.35)
Rivaroxaban

0.58
1.25
0.70
(0.32 to 1.05) (0.87 to 1.78) (0.42 to 1.18)
Aspirin +
Ticagrelor

2.13
1.20
(1.20 to 3.85) (0.69 to 2.09)
0.56
Aspirin +
Rivaroxaban (0.34 to 0.93)
Aspirin +
Clopidogrel

Major bleeding
Placebo

2.98
5.31
4.86
4.45
2.96
5.74
2.53
(0.31 to 28.2) (0.56 to 50.2) (0.20 to 119) (0.42 to 47.0) (0.28 to 31.8) (0.31 to 106) (0.21 to 30.0)
Aspirin

1.78
1.63
1.50
0.99
1.93
0.85
(0.95 to 3.34) (0.17 to 15.9) (0.73 to 3.04) (0.46 to 2.14) (0.30 to 12.4) (0.30 to 2.37)
0.91
0.84
0.56
1.08
0.48
Vitamin K
antagonists (0.09 to 9.69) (0.32 to 2.16) (0.21 to 1.50) (0.15 to 7.69) (0.14 to 1.59)
Ticagrelor

0.92
0.61
1.18
0.52
(0.08 to 9.93) (0.06 to 6.71) (0.24 to 5.91) (0.05 to 5.39)
Rivaroxaban

0.66
1.29
0.57
(0.33 to 1.33) (0.18 to 9.42) (0.16 to 1.98)
1.94
0.86
Aspirin +
Rivaroxaban (0.26 to 14.5) (0.24 to 3.08)
Aspirin +
Ticagrelor

0.44
(0.07 to 2.97)
Aspirin +
Clopidogrel

Fig 3 | Network meta-analysis and certainty of evidence for saphenous vein graft failure (primary efficacy outcome) and major bleeding (primary
safety outcome). Results are odds ratios (95% confidence intervals) from the network meta-analysis between the column defining intervention
and row defining intervention. Significant results are in bold. Certainty of evidence is also given: green=moderate certainty evidence, yellow=low
certainty evidence, red=very low certainty evidence
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Table 3 | Summary of network meta-analysis estimates of effects, confidence intervals, and certainty of evidence for the comparison of different
antithrombotic drugs in patients undergoing coronary artery bypass graft surgery
Anticipated absolute effect, per 1000 patients†
(95% CI)

Relative effect,
ASA
odds ratio (95%
Comparator (reference):
monotherapy
CI)*
ASA monotherapy
SVGF§ (total studies: 20 RCTs; total participants: 4803):
ASA+tica
0.50 (0.31 to 0.79),
230
(2 RCTs; 420 participants)
network estimate
ASA+clopi
0.60 (0.42 to 0.86),
150
(6 RCTs; 1118 participants)
network estimate

Other
strategies

130
96

Difference

Certainty of evidence*

100 fewer
(145 to 39 fewer)
54 fewer
(81 to 18 fewer)

⊕⊕⊕○, moderate,
due to indirectness
⊕⊕⊕○, moderate,
due to indirectness

ASA+riva
(1 RCT; 1401 participants)

1.06 (0.75 to 1.50),
99
network estimate

104

5 more
(23 fewer to 43 more)

⊕⊕○○, low, due to

Tica monotherapy
(1 RCT; 332 participants)

0.80 (0.49 to 1.29),
283
network estimate

240

43 fewer
(121 fewer to 54 more)

⊕⊕○○, low, due to

Riva monotherapy
(1 RCT; 1351 participants)

0.85 (0.59 to 1.23),
99
network estimate

85

14 fewer
(38 fewer to 20 more)

⊕⊕○○, low, due to

VKA
(2 RCTs; 601 participants)

1.00 (0.71 to 1.41),
284
network estimate

284

0 fewer
(64 fewer to 75 more)

Clopi monotherapy (no direct
evidence, indirect evidence only)

1.14 (0.35 to 3.69)

112

12 more
(63 fewer to 191 more)

377

122 more
(55 to 195 more)

100¶

Placebo
1.77 (1.31 to 2.39),
255
(7 RCTs; 831 participants)
network estimate
Major bleeding (total studies: 11 RCTs; total participants: 3745):

indirectness and imprecision
indirectness and imprecision
indirectness and imprecision

⊕○○○, very low, due to

risk of bias, indirectness,
and imprecision
⊕○○○, very low, due to
intransitivity, indirectness,
and imprecision
⊕⊕⊕○, moderate, due to
indirectness

Placebo
(2 RCTs; 385 participants)

0.34 (0.04 to 3.23),
8
network estimate

3

5 fewer
(7 fewer to 16 more)

⊕⊕○○, low, due to

ASA+clopi
(5 RCTs; 518 participants)

0.85 (0.30 to 2.37),
33
network estimate

28

5 fewer
(23 fewer to 42 more)

⊕⊕○○, low, due to

ASA+riva
(1 RCT; 965 participants)

0.99 (0.46 to 2.14),
28
network estimate

28

0 fewer
(15 fewer to 30 more)

⊕⊕⊕○, moderate, due to
imprecision

Riva
(1 RCT; 946 participants)

1.50 (0.73 to 3.04),
28
network estimate

41

13 more
(7 fewer to 53 more)

⊕⊕⊕○, moderate,
due to imprecision

Tica
(1 RCT; 332 participants)

1.63 (0.17 to 15.9),
3
network estimate

5

2 more
(2 fewer to 43 more)

⊕⊕⊕○, moderate,
due to imprecision

ASA+tica
(2 RCTs; 404 participants)

1.93 (0.30 to 12.4),
12
network estimate

23

11 more
(9 fewer to 123 more)

⊕⊕⊕○, moderate,
due to imprecision

VKA
(2 RCTs; 755 participants)

1.78 (0.95 to 3.34),
42
network estimate

74

31 more
(2 fewer to 88 more)

indirectness and imprecision
indirectness and imprecision

⊕○○○, very low, due to
risk of bias, indirectness
and imprecision

NNT/NNH
(95% CI)

NNT: 10
(7 to 26)
NNT: 19
(13 to 55)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)
NNH: 9 (6 to 19)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)
Not calculated
(non-statistically
significant)

SUCRA‡

94.4
85.3
32.9
61.3
58.3
39.7
36.2
3.3

84.4
66.5
61.1
33.6
38.6
29.8
24.4

ASA=aspirin; clopi=clopidogrel; NNH=number needed to harm; NNT=number needed to treat; RCT=randomised controlled trial; riva=rivaroxaban; SUCRA=surface under the cumulative ranking;
SVGF=saphenous vein graft failure; tica=ticagrelor; VKA=vitamin K antagonist.
*Significant results are in bold.
†Data obtained directly from study sample (studies reporting outcome data), unless stated otherwise.
‡Larger SUCRA values indicate better interventions and higher hierarchy ranks are in bold.
§Saphenous vein graft failure (base case analysis), range of follow-up between one month and eight years.
¶Assumed risk (risk was assumed because of lack of direct evidence).

analysis, and two of these16 27 clearly reported the
use of intention to treat analysis with worst case
assumptions for imputation of missing data. It was
unclear how the remaining trials with incomplete data
handled missing outcome data.
Figure 3 (top panel) also provides the certainty of
evidence of network estimates for saphenous vein
graft failure. We downgraded evidence certainty to
low or very low for most comparisons, mainly because
of study limitations owing to incomplete outcome
data, imprecision, indirectness, and the possibility
of intransitivity. Supplementary tables 8 and 9
summarise certainty of evidence for direct, indirect,
8

and network estimates. The network evidence for dual
antiplatelet therapy with aspirin plus ticagrelor and
aspirin plus clopidogrel was of moderate certainty
compared with aspirin monotherapy. The symmetrical
comparison adjusted funnel plot shows neither
evidence of publication bias for placebo controlled
trials nor small study effects (supplementary figure
1). When we performed a sensitivity analysis that
excluded studies considered at serious risk of bias,
the effect estimates did not change substantially,
except for aspirin plus clopidogrel versus vitamin
K antagonist, which became non-significant
(supplementary figure 2).
doi: 10.1136/bmj.l5476 | BMJ 2019;367:l5476 | the bmj

RESEARCH

All cause mortality

Aspirin and clopidogrel
1 trial
3 trials

Aspirin and
ticagrelor

Aspirin

2 trials

Vit K A

4 trials
2 trials

Placebo
Myocardial infarction
Aspirin and ticagrelor
1 trial

Vit K A

Aspirin and
clopidogrel

2 trials
2 trials

1 trial

5 trials

1 trial

2 trials

Aspirin

Placebo
1 trial

Aspirin and
rivaroxaban

1 trial

1 trial
Rivaroxaban

1 trial
Ticagrelor

Fig 4 | Network of treatment comparisons for secondary outcomes all cause mortality and myocardial infarction.
Each node represents different active interventions or placebo. Size of nodes is proportional to number of studies
comparing respective nodes. Increasing thickness of lines between nodes is proportional to number of randomly
assigned patients contributing to direct comparisons. Vit K A=vitamin K antagonist

We also downgraded the certainty of evidence to low
or very low for most comparisons of clinical outcomes,
including major bleeding, myocardial infarction, and
mortality (fig 3, bottom panel, fig 5, and supplementary
tables 8 and 9). However, comparisons with moderate
certainty evidence should be interpreted with caution
mainly because of inconsistency and publication bias.
We could not thoroughly assess inconsistency because
many of the comparisons consisted of a single study.
Additionally, we could not assess publication bias
for secondary outcomes because this network metaanalysis was designed to exclude studies that did not
evaluate our primary efficacy outcome (saphenous
vein graft failure), regardless of reported secondary
outcomes (supplementary tables 8 and 9).
the bmj | BMJ 2019;367:l5476 | doi: 10.1136/bmj.l5476

Network assumptions
The distribution of potential effect modifiers was not
balanced across comparisons; however, the evidence
of intransitivity was inconclusive because of missing
data in several comparisons (table 2). While we could
not rule out the possibility of intransitivity (lack of
similar characteristics across the studies and treatment
comparisons), between-trial heterogeneity (τ2) was low
in all included analyses compared with the expected
value reported in the literature.49 Supplementary table
9 shows direct and indirect estimates, and τ2. Loop
specific approach (supplementary table 10) and design
by treatment interaction models (supplementary table
11) showed no evidence of incoherence between direct
and indirect comparisons for all analyses.
9
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All cause mortality
Placebo

1.77
(0.52 to 5.99)

1.04
(0.23 to 4.72)

1.24
(0.01 to 114)

1.24
(0.13 to 11.5)

Aspirin

0.59
(0.19 to 1.87)

0.70
(0.01 to 54.3)

0.70
(0.11 to 4.50)

Vitamin K
antagonists

1.19
(0.01 to 107)

1.19
(0.13 to 10.6)

Aspirin +
Ticagrelor

1.00
(0.02 to 51.1)
Aspirin +
Clopidogrel

Myocardial infarction
Placebo

0.49
(0.11 to 2.11)

0.45
(0.10 to 2.00)

0.33
(0.03 to 3.28)

0.47
(0.08 to 2.84)

0.34
(0.04 to 2.84)

0.25
(0.04 to 1.73)

0.34
(0.06 to 2.05)

Aspirin

0.92
(0.52 to 1.63)

0.68
(0.12 to 3.97)

0.96
(0.33 to 2.75)

0.70
(0.15 to 3.22)

0.52
(0.15 to 1.80)

0.71
(0.26 to 1.96)

Vitamin K
antagonists

0.74
(0.12 to 4.71)

1.04
(0.31 to 3.45)

0.76
(0.15 to 3.88)

0.57
(0.15 to 2.21)

0.77
(0.24 to 2.46)

Ticagrelor

1.40
(0.18 to 10.93)

1.03
(0.16 to 6.80)

0.77
(0.09 to 6.58)

1.04
(0.14 to 7.68)

Rivaroxaban

0.74
(0.12 to 4.68)

0.55
(0.16 to 1.88)

0.74
(0.17 to 3.20)

Aspirin +
Ticagrelor

0.74
(0.10 to 5.27)

1.00
(0.18 to 5.74)

Aspirin +
Rivaroxaban

1.35
(0.27 to 6.70)
Aspirin +
Clopidogrel

Fig 5 | Network meta-analysis and certainty of evidence for secondary outcomes all cause mortality and myocardial infarction. Results are odds ratios
(95% confidence intervals) from the network meta-analysis between the column defining intervention and the row defining intervention. Certainty of
evidence is also given: green=moderate certainty evidence, yellow=low certainty evidence, red=very low certainty evidence

Discussion
Principal findings
This systematic review included 20 parallel group
randomised controlled trials of 4803 patients under
going coronary artery bypass graft. The review com
pared eight active antithrombotic interventions in a
single framework to assess saphenous vein graft failure.
The results of this network meta-analysis suggest that
among active interventions and based on moderate
certainty evidence, dual antiplatelet therapies with
aspirin plus ticagrelor or aspirin plus clopidogrel were
the most efficacious treatment regimens to prevent
saphenous vein graft failure compared with aspirin
monotherapy. However, the tradeoff was an increased
risk of major bleeding, although the risk did not differ
among the drug interventions.
Strengths and limitations of the study
The strength of our analysis is its robust design and
transparency. We prespecified the research question
and published a peer reviewed protocol23 for this
systematic review of published randomised controlled
trials of drug interventions to prevent saphenous vein
graft failure after coronary artery bypass graft surgery.
To increase the totality of evidence, we accounted for
10

clustering effects of data expressed on a per graft basis,
and made an inference at the patient level, which
improved the applicability of the results in light of a
newer P2Y12 inhibitor (ticagrelor) and direct factor Xa
inhibitor (rivaroxaban). Our analysis adds new data
on the use of dual antiplatelet therapy with aspirin
plus ticagrelor and direct oral anticoagulation with
rivaroxaban, thereby providing a better understanding
of the role of these drug interventions to prevent
saphenous vein graft failure after coronary artery
bypass graft surgery.
The certainty of evidence for the saphenous vein
graft failure endpoint was considered low or moderate
for making a recommendation for most treatments
compared with aspirin. Therefore, additional well
designed research might change the findings.
For clinical (secondary) outcomes, the results of our
network meta-analysis show no differences in effect
estimates among multiple treatment comparisons;
nonetheless, these were not our prespecified primary
outcomes. Interestingly, the recently published and
prematurely terminated trial that compared ticagrelor
with aspirin after coronary artery bypass graft surgery
showed no important differences in major adverse
cardiovascular events or bleeding between the
doi: 10.1136/bmj.l5476 | BMJ 2019;367:l5476 | the bmj
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monotherapies.50 These findings support the need for
studies that evaluate dual antiplatelet therapy after
coronary artery bypass graft surgery. Although our
study might be underpowered to detect differences
in clinical outcomes, further and larger randomised
controlled trials that compare all the relevant
antithrombotic strategies after coronary artery bypass
graft surgery will be difficult to undertake with a mixed
treatment comparison design. Therefore, our study is
clinically meaningful and contributes up to date data
to guide future directions in preventing saphenous
vein graft failure after coronary artery bypass graft
surgery.
In this study, we used a frequentist framework
to perform the analysis as opposed to a Bayesian
approach because the results of Bayesian analysis with
non-informative priors are numerically equivalent
to frequentist results. Although informative priors
would make Bayesian methods more appealing than
a frequentist framework, especially when dealing
with small studies, such priors were not available.
Therefore, the risk of using inaccurate informative
priors can cause even more damage to the validity of
the results.
Our study has several limitations. First, the quality
of our analysis is limited by the inherent limitations
of individual included trials. In particular, patient
level data were not available, which precluded
adjustment for any differences in clinical setting;
for example, stable coronary artery disease versus
acute coronary syndromes, elective versus urgent
surgery, and on pump versus off pump coronary
artery bypass graft surgery. In this study, more than
80% of the patients underwent elective coronary
artery bypass graft surgery; moreover, in the acute
coronary syndrome setting, there is consensus among
international guidelines that dual antiplatelet therapy
is resumed soon after surgery and continued for one
year (class I).2 51 52 Also, we were unable to perform
competing risk analysis. If we had reported measures
of effects that reflect time to event (that is, hazard
ratio), the results would have been more informative.
However, the studies that were eligible for this review
did not report these measures.
Second, although we presented full details about the
risk of bias of all included trials (supplementary table
7), many trials did not report adequate information
about allocation sequence concealment, proportions of
and reasons for missing outcome data, and how trials
handled missing data. This lack of information could
have led to inaccurate interpretation of the certainty of
evidence. Third, different trials used different outcome
definitions and also various imaging follow-up protocols,
which could have threatened the internal validity of our
network meta-analysis. Although our sensitivity analysis
showed no substantial differences in effect estimates
between per graft and per patient analyses for most
comparisons, the credibility of this data driven approach
remains unclear. Fourth, we combined studies using
different doses of the same drug intervention in the same
node, and assumed that there would be no systematic
the bmj | BMJ 2019;367:l5476 | doi: 10.1136/bmj.l5476

differences in treatment effects across doses. Fifth, the
trials in which most of patients underwent off pump
coronary artery bypass graft surgery,16 35 36 the dose of
aspirin (monotherapy or dual antiplatelet therapy) was
81-100 mg daily. However, we were unable to compare
and confirm the potential benefit of higher doses (such
as 160-325 mg) of aspirin in patients undergoing
off pump procedures because of a lack of off pump
trials using these doses of aspirin. Nevertheless, when
combined with a P2Y12 inhibitor, the recommended
dose of aspirin is less than 100 mg daily.
Sixth, our network meta-analysis included trials
published over a 39 year period, which might not reflect
the current clinical practice; for example, patient
characteristics, surgical techniques (eg, off pump
coronary artery bypass graft), drug regimens (early
trials were more likely to compare against placebo and
later trials were more likely to be active comparator
trials), and secondary prevention strategies18 (sta
tins, angiotensin converting enzyme inhibitors, or
angiotensin receptor blockers and β blockers). There
fore, changes in adjunct medical treatment over time
could potentially affect treatment estimates. Post hoc
meta-regression analysis did not show evidence of
an association between treatment effect and year of
publication for some treatments. However, it was not
possible to estimate the effect of publication year for
all treatments owing to multicollinearity and missing
linkage (supplementary table 12). We performed a
sensitivity analysis stratified by publications before
and after the year 2000 (supplementary figure 3), and
the findings did not change the treatment effect when
the results were split by more recent trials. Finally,
legacy or post trial persistent treatment effect was
explored. While the sensitivity analysis did not change
the effect estimates, this was based on a single study
that reported saphenous vein graft failure at one37and
eight24 years.

Comparison with other studies
Aspirin monotherapy is currently recommended
for patients with stable coronary artery disease
after coronary artery bypass graft surgery to reduce
saphenous vein graft failure.18 In patients who present
with acute coronary syndromes, dual antiplatelet
therapy is recommended to be resumed soon after
coronary artery bypass graft surgery.2 51 52 However,
there is a lack of evidence that dual antiplatelet therapy
is associated with a decrease in thromboembolic
complications or mortality in patients with stable
coronary artery disease undergoing coronary artery
bypass graft surgery.53 Few observational and
randomised data suggest that additional drug
intervention with dual antiplatelet therapy reduces
the risk of saphenous vein graft failure. This effect
appears to be more pronounced in patients undergoing
off pump coronary artery bypass graft surgery than
on pump coronary artery bypass graft surgery, or for
arterial graft recipients.54 55
The 2016 American guidelines51 recommend that
in patients with stable coronary artery disease, aspirin
11
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81 mg (75-100 mg) plus clopidogrel (started early after
surgery) for 12 months after coronary artery bypass
graft might be reasonable to improve saphenous vein
graft patency (class IIb, level of evidence B). Conversely,
the 2017 European guidelines state that there is
insufficient evidence to generally recommend dual
antiplatelet therapy to reduce saphenous vein graft
failure.53 To mitigate the relative hypercoagulable state
that off pump patients experience, the 2015 American
Heart Association scientific statement18 recommends
the combination of aspirin and clopidogrel after off
pump coronary artery bypass graft surgery (class I,
level of evidence A). However, the European guidelines
state that there is weak evidence to support dual
antiplatelet therapy in this subset of patients,53 and
the American guidelines51 do not comment on this.
The clinical benefits of adding a P2Y12 inhibitor
to aspirin originate from the Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE) trial.
Participants with non-ST elevation acute coronary
syndromes who were allocated to receive aspirin
plus clopidogrel experienced a major reduction in
the composite outcome of death from cardiovascular
causes, non-fatal myocardial infarction, or stroke, and
a range of related ischaemic events.56 However, there
was a tradeoff of increased risk of bleeding, and most
of the major bleeding events were gastrointestinal and
arterial access site bleeds.56 In our analysis, although
the occurrence of major bleeding with aspirin plus
ticagrelor was not statistically significant compared
with aspirin alone, the network estimates showed an
odds ratio of 1.93, and wide 95% confidence intervals
(0.30 to 12.4) compared with aspirin plus clopidogrel
(0.85, 0.30 to 2.37). The lack of different doses of
clopidogrel precludes further analysis. Notably, the
combination of aspirin plus rivaroxaban 2.5 mg
twice daily or rivaroxaban 5 mg twice daily alone did
not reduce saphenous vein graft failure compared
with aspirin alone in the COMPASS (Cardiovascular
OutcoMes for People Using Anticoagulation StrategieS)
coronary artery bypass graft trial.17 However, the
combination of aspirin plus rivaroxaban 2.5 mg twice
daily was associated with similar reductions in major
adverse cardiovascular events, and this was consistent
with the findings of the main COMPASS trial.57
Therefore, because major bleeding has been associated
with increased morbidity and mortality,58 59 the risk
of bleeding should be carefully balanced against the
benefits when planning long term (>12 months) dual
antiplatelet therapy in patients undergoing coronary
artery bypass graft surgery.

Unanswered questions and future research
We did not have enough power to detect significance for
clinical outcomes because we restricted the inclusion
to trials that reported saphenous vein graft failure (our
primary outcome), hence reducing statistical power
in this regard. However, the eligibility criteria were
purposefully stringent to reduce heterogeneity and risk
of bias. Saphenous vein graft failure is not a clinical
outcome in itself; it is considered a surrogate endpoint
12

of myocardial infarction or repeat revascularisation.
However, not all saphenous vein grafts are the same
because of individual graft quality or technical (that
is, anastomoses) matters. Additionally, the grafts
depend on which are the target vessels, the severity of
stenosis and ischemia,60 and the territory and amount
of myocardium being supplied by a given graft. Hence,
saphenous vein graft failure will occur because
of physiological or functional causes rather than
saphenous vein graft driven thrombotic mechanisms,
yet without apparent clinical consequence.60 61 Lopes
and colleagues61 showed that saphenous vein graft
failure was associated with an increased risk for the
composite of death, myocardial infarction, or repeat
revascularisation at four years after the angiogram.
However, this association was mainly because of repeat
revascularisation; there were no differences in terms
of death or the composite of death and myocardial
infarction among individuals with and without
saphenous vein graft failure.61 These findings highlight
the confounded association between saphenous
vein graft failure and major adverse cardiovascular
events. Therefore, when saphenous vein graft failure is
accompanied by clinical symptoms,61 for example new
onset angina and progressive symptoms of angina,
or hospital admission for acute coronary syndromes
leading to revascularisation, this could be more
relevant for prognosis and patient preferences and
values.
Not all the included trials reported the actual data
on duration of treatment. Therefore, patients might
have received different durations of antithrombotic
treatments, which resulted in patient level covariate
effects. Post hoc meta-regression analysis did not
show evidence of an association between duration of
treatment (originally prespecified by the trial authors,
not actual duration) and treatment effect for some
drug interventions; however, it was not possible
to estimate the effect of treatment duration for all
treatments because of multicollinearity and missing
linkage (supplementary table 13). Moreover, this metaregression probably had low power to detect such an
association, and its credibility is questionable owing to
the lack of patient level data; therefore, it is subject to
ecological bias.
Further research is needed to improve strategies to
optimise saphenous vein graft patency after coronary
artery bypass graft surgery. We need studies of adequate
duration and sample size that report saphenous vein
graft failure at different time points to determine the
potential legacy effect of dual antiplatelet therapy
during the first year after coronary artery bypass graft
surgery. Additionally, these studies should report long
term (that is, five or 10 years) incidence of saphenous
vein graft failure, and patient important outcomes
(mortality, ischaemic, or bleeding events).

Conclusion and policy implications
The results of this network meta-analysis suggest an
important absolute benefit of adding ticagrelor or
clopidogrel to aspirin to prevent saphenous vein graft
doi: 10.1136/bmj.l5476 | BMJ 2019;367:l5476 | the bmj
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failure after coronary artery bypass graft surgery. Dual
antiplatelet therapy after surgery should be tailored to
the patient by balancing the safety and efficacy profile
of the drug intervention against important patient
outcomes. Future guideline updates are needed to
optimise antithrombotic management of patients
undergoing coronary artery bypass graft surgery.
Meanwhile, dual antiplatelet therapy with aspirin
plus ticagrelor or aspirin plus clopidogrel could be
considered for most patients after surgery.
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